[1] GAN L, WANG J, JIANG M, et al. Recent advances in topical ophthalmic drug delivery with lipidbased nanocarriers[J]. Drug Discov Today, 2013, 18(5):290-297.
[2] LIU Y, WANG Y N, YANG J L, et al. Cationized hyaluronic acid coated spanlastics for cyclosporine A ocular delivery: prolonged ocular retention, enhanced corneal permeation and improved tear production[J]. Int J Pharm, 2019, 565:133-142.
[3] KANG H, CHA K H, CHO W, et al. Cyclosporine A micellar delivery systerm for dry eyes[J]. Int J Nanomed, 2016, 11:2921-2933.
[4] JOHANNSDOTTIR S, KRISTINSSON J K, FULOP Z, et al. Formulations and toxicologic in vivo studies of aqueous cyclosporin A eye drops with cyclodextrin nanoparticles[J]. Int J Pharm, 2017, 529:486-490.
[5] WU X G, XIN M, SHI W Y. The preparation and ocular biological characters of mycophenolate mofetil nanosuspension in rabbits[C]. Changsha: Chinese Pharmceutical Association, 2010.
[6] BABA K, TANAKA Y, KUBOTA A, et al. A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolyzable dye[J]. J Controlled Release, 2011,153(3):278-287.
[7] NAGAI N, YOSHIOKAC, MANO Y, et al. A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure[J]. Exp Eye Res, 2015, 132:115-123.
[8] SHARMA O P, PATEL V, MEHTA T, et al. Nanocrystal for ocular drug delivery: hope or hype[J]. Drug Deliv Transl Res, 2016, 6(4): 399-413.
[9] KIM J H, JANG S W, HAN S D, et al. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods[J]. Pharmazie, 2011, 66(7): 491-495.
[10] LALLEMAND F, FURRER P, FELT-BAEYENS O, et al. A novel water-soluble cyclosporine A prodrug: ocular tolerance and in vivo kinetics[J]. Int J Pharm, 2005, 295(1-2): 7-14.
[11] YA EZ-SOTO B, MANNIS M J, SCHWAB I R, et al. Interfa- cial phenomena and the ocular surface[J]. Ocular Surf, 2014, 12(3): 178-201.
[12] MANNER, MAA E, VELLONEN K S, et al. Drug transport in corneal epithelium and blood retina barrier: emerging role of transporters in ocular pharmacokinetics[J]. Adv Drug Deliv Rev, 2006, 58(11): 1136-1163.
[13] YOU W, QIAN F, WU C, et al. Barriers and methods of ocular drug delivery[J]. Int Pharm Res J(国际药学研究杂志), 2008, 35(4): 284-287.
[14] KIM J H, JANG S W, HAN S D, et al. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods[J]. Pharmazie, 2011, 66(7): 491-495.
[15] LYSENG-WILLIAMSON K A. Cationorm (cationic emulsion eye drops) in dry eye disease: a guide to its use[J]. Drugs Ther Perspect, 2016, 32(8): 317-322.
[16] PHILIPPE D, JEAN S, BASTIEN G, et al. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery [J]. J Pharm Pharmacol, 2014, 66(4): 531-541
[17] SUN PHARMACETICAL INDUSTRIES, INC. CEQUA^TM (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use[DB/OL]. US Food and Drug Administration, 2019 [2019-09-03]. https://www.drugfuture.com/fda-ndc/label.aspx?ProductNDC=47335-506.
[18] YUE P F, LIU Y, XIE J, et al. Review and prospect on preparation technology of drug nanocrystals in the past thirty years[J]. Acta Pharm Sin(药学学报), 2018, 53(4): 529-537.
[19] GIGLIOBIANCO M R, CASADIDIO C, CENSI R, et al. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability[J]. Pharmaceutics, 2018, 10(3): 134-163.
[20] CAMASMIE P M C, DOS SANTOS N E, MONTEIRO L M, et al. Advances in ophthalmic preparation: the role of drug nanocrystals and lipid-based nanosystems[J]. J Drug Target, 2019,28(3):259-270.
[21] ZHOU X Y, LI J L, WANG Y M, et al. Application of new formulations in ocular drug delive system[J]. Chin New Drugs J(中国新药杂志), 2020, 29(1): 55-62.
[22] ALI H S, YORK P, BLAGDEN N, et al. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling[J]. J Controlled Release, 2011, 149(2):175-181.
[23] KASSEM M, RAHMAN A A, GHORAB M, et al. Nanosuspension as an ophthalmic delivery system for certain glu-cocorticoid drugs [J]. Int J Pharm, 2007, 340(1): 126-133.
[24] ROMERO G B, KECK C M, RAINERR H, et al. Development of cationic nanocrystals for ocular delivery[J]. Eur J Pharm Biopharm, 2016, 107: 215-222.
[25] BABA K, NISHIDA K. Steroid nanocrystals prepared using the nano spray dryer B-90[J]. Pharmaceutics, 2013, 5(1):107-114.
[26] NAGAI N, ONO H, HASHINO M, et al. Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles[J]. J Oleo Sci, 2014, 63(2):177-186.
[27] NAGAI N, ITO Y, OKAMOTO N, et al. A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability[J]. Toxicology, 2014, 319: 53-62.
[28] SAORI D, HIROKO O, YOSUKE N, et al. Ophthalmic formulation containing nilvadipine nanoparticles prevents retinal dysfunction in rats injected with streptozotocin[J]. Int J Mol Sci, 2017, 18(12): 2720.
[29] TUOMELA A, LIU P, PURANEB J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo[J]. Int J Pharm, 2014, 467(1-2):34-41.
[30] GUPTA S, SAMANTA M K, RAICHUR A M, et al. Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy[J]. AAPS Pharm Sci Tech, 2010, 11(1): 322-335.
[31] SCHOPF L, ENLOW E, POPOV A, et al. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation[J]. Ophthalmol Ther, 2014, 3(1-2):63-72.
[32] BABA K, NISHIDA K, HASHIDA N. Method for producing an aqueous dispersion of drug nanoparticles and use thereof: US, 20150087624[P]. 2015.
[33] SMART J D. The basics and underlying mechanisms of mucoadhe- sion[J]. Adv Drug Deliv Rev, 2005, 57 (11): 1556-1568.
[34] GAO L, ZHANG D, CHEN M, et al. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system[J]. J Nanoparticle Res, 2008,10(5): 845-862.
[35] MAKHLOF A, MIYAZAKI Y, TOZUKA Y, et al. Cyclodextrins as stabilizers for the preparation of drug nanocrystals by the emulsion solvent diffusion method[J]. Int J Pharm, 2008, 357(1-2):280-285.
[36] SHETE G, JAIN H, PUNJ D, et al. Stabilizers used in nano-crystal based drug delivery systems[J]. Int Pharm Excipients Council, 2014, 5(4):184-209.
[37] KAUR J, KUMAR S. Devolepment of nanocrystal formulation with improved dissolution [J]. J Drug Deliv Ther, 2018, 8(5):118-129.
[38] ANNIKA T, JOUNI H, LEENA P, et al. Stabilizing agents for drug nanocrystals: effect on bioavailability[J]. Pharmaceutics, 2016, 8(2):16-34.
[39] LIST M, SUCKER H. Pharmaceutical colloidal hydrosols for injection: GB, 2200048 [P]. 1988-07-27.
[40] AUWETER H, BOHN H, HEGER R, et al. Precipitated water insoluble colorants in colloid disperse form: US, 6494924 [P]. 2002-12-17.
[41] KECK C M, MÜLLER R H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization [J]. Eur J Pharm Biopharm, 2006, 62: 3-16.
[42] MAJURU S, OYEWUMI M O. Nanotechnology in Drug, Development and Life Cycle Management. DE VILLIERS M M, ARAMWIT P, KWON G S Nanotechnology in Drug Delivery[M]. New York: Springer, 2009: 597-619.
[43] MULLER R H, BECKER R, KRUSS B, et al. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution: US, 5858410 A [P]. 1999-01-12.
[44] HELMUT M R, KARSTEN K, KARSTEN M. Verfahren zur schonenden Herstellung von hochfeinen mikropartikeln und nanopartikeln: Germany, DE19932157A [P]. 2001-01-18.
[45] KIPP J E, WONG J C T, DOTY M J, et al. Microprecipitation method for preparing submicron suspensions: US, 6607784 [P]. 2003-08-19.
[46] SHARMA O P, PATEL V, MEHTA T. Nanocrystal for ocular drug delivery: hope or hype [J]. Drug Deliv Transl Res, 2016, 6: 399-413.
[47] MÖSCHWITZER J, LEMKE A. Method for carefully producing ultrafine particle suspensions and ultrafine particles and use: EP, 2006/003377 [P]. 2006-10-19.
[48] PETERSEN R. Nanocrystals for use in topical cosmetic formulations and method of production thereof: US, 9114077 [P]. 2015-08-25.
[49] SCHOLZ P, ARNTJEN A, MÜLLER R H, et al. ARTcrystal^® process for industrial nanocrystals production optimization of the ART MICCRA pre-milling step [J]. Int J Pharm, 2014, 465: 388-395.
[50] WANG Y, ZHENG Y, ZHANG L, et al. Stability of nanosuspensions in drug delivery[J]. J Controlled Release, 2013, 172(3):1126-1141.
[51] LIU P, VIITALA T, KARTAL-HODZIC A, et al. Interaction studies between indomethacin nanocrystals and PEO/PPO copolymer stabilizers[J]. Pharm Res, 2015, 32(2): 628-639.
[52] VAN EERDENBRUGH B, VERMANT J, MARTENS J A, et al. A screening study of surface stabilization during the production of drug nanocrystals[J]. J Pharm Sci, 2009, 98(6): 2091-2103.
[53] TUOMELA A, LAAKSONEN T, LARU J, et al. Solid formulations by a nanocrystal approach: critical process parameters regarding scale-ability of nanocrystals for tableting applications[J]. Int J Pharm, 2015, 485(1-2): 77-86.